glp 1 and colitis The alleviating effect mechanism of GLP-1 on ulcerative Small peptide encoded by MALAT1

Multiple clinical studies show EVOO increases postprandial GLP-1 and PYY (satiety hormones) while reducing ghrelin (the hunger hormone), through mechanisms that partially overlap with what GLP-1 drugs do pharmacologically

PYY delayed gastric emptying and inhibited gastric and pancreatic secretion and gall-bladder emptying while increasing ileal postprandial fluid and electrolyte absorption (67-69)

10.1002/humu.21607 Hum

The 20.9% mean body weight reduction seen in SURMOUNT-1 at 72 weeks reflects tirzepatides direct receptor binding and metabolic effects, not secondary antioxidant support

Intravenous glutathione Due to the low bioavailability of oral glutathione, intravenous injections are being promoted to provide desired therapeutic levels in the blood and skin and to produce instant skin-lightening